Federal contract award
75N91020F00003
PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND ENDPOINT BIOMARKERS. TASK ORDER TITLE: URINARY BLADDER CANCER PREVENTION WITH TWO CLINICALLY-READY AGENTS (EVEROLIMUS AND NAPROXEN)WHEN ADMINISTERED IN COMBINATION.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NIH NCI |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH |
| Parent award / vehicle | 75N91019D00020 |
| Set-aside | Not reported |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $780.9K |
| Current contract value | $780.9K |
| Potential contract value / ceiling | $780.9K |
| Start date | Sep 21, 2020 |
| Current end date | Jun 20, 2025 |
| Potential end date | Jun 20, 2025 |
| Latest award activity | May 5, 2025 |
| Source loaded | Aug 15, 2026 |
Funding and modification history
Showing the latest 6 of 6 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| May 5, 2025 | P00005 | $-4.3K | TASK ORDER TITLE: URINARY BLADDER CANCER PREVENTION WITH TWO CLINICALLY-READY AGENTS (EVEROLIMUS AND NAPROXEN) WHEN ADMINISTERED IN COMBINATION. |
| Oct 22, 2024 | P00004 | $0 | TASK ORDER TITLE: URINARY BLADDER CANCER PREVENTION WITH TWO CLINICALLY-READY AGENTS (EVEROLIMUS AND NAPROXEN) WHEN ADMINISTERED IN COMBINATION. |
| Apr 25, 2024 | P00003 | $0 | TASK ORDER TITLE: URINARY BLADDER CANCER PREVENTION WITH TWO CLINICALLY-READY AGENTS (EVEROLIMUS AND NAPROXEN) WHEN ADMINISTERED IN COMBINATION. |
| Aug 17, 2023 | P00002 | $0 | TASK ORDER TITLE: URINARY BLADDER CANCER PREVENTION WITH TWO CLINICALLY-READY AGENTS (EVEROLIMUS AND NAPROXEN) WHEN ADMINISTERED IN COMBINATION. |
| Aug 9, 2022 | P00001 | $0 | TASK ORDER TITLE: URINARY BLADDER CANCER PREVENTION WITH TWO CLINICALLY-READY AGENTS (EVEROLIMUS AND NAPROXEN) WHEN ADMINISTERED IN COMBINATION. |
| Sep 9, 2020 | 0 | $785.2K | PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND ENDPOINT BIOMARKERS. TASK ORDER TITLE: URINARY BLADDER CANCER PREVENTION WITH TWO CLINICALLY-READY AGENTS (EVEROLIMUS AND NAPROXEN)WHEN ADMINISTERED IN COMBINATION. |
Research next steps
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.